Hyman Charles D Has $1.99 Million Holdings in Amgen Inc. (NASDAQ:AMGN)


Share on StockTwits

Hyman Charles D cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,002 shares of the medical research company’s stock after selling 900 shares during the period. Hyman Charles D’s holdings in Amgen were worth $1,991,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in AMGN. Ironwood Financial llc lifted its position in Amgen by 35.6% in the first quarter. Ironwood Financial llc now owns 6,380 shares of the medical research company’s stock valued at $1,587,000 after purchasing an additional 1,675 shares during the last quarter. GW Henssler & Associates Ltd. increased its position in shares of Amgen by 3.3% in the first quarter. GW Henssler & Associates Ltd. now owns 76,997 shares of the medical research company’s stock valued at $19,158,000 after acquiring an additional 2,470 shares during the period. Meeder Asset Management Inc. increased its position in shares of Amgen by 499.0% in the first quarter. Meeder Asset Management Inc. now owns 42,532 shares of the medical research company’s stock valued at $10,582,000 after acquiring an additional 35,432 shares during the period. Regent Peak Wealth Advisors LLC boosted its stake in Amgen by 16.3% during the first quarter. Regent Peak Wealth Advisors LLC now owns 8,000 shares of the medical research company’s stock worth $1,990,000 after acquiring an additional 1,121 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. grew its stake in Amgen by 34.4% during the 1st quarter. NN Investment Partners Holdings N.V. now owns 119,718 shares of the medical research company’s stock valued at $29,787,000 after purchasing an additional 30,612 shares during the last quarter. 75.23% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on AMGN shares. Oppenheimer dropped their target price on Amgen from $275.00 to $265.00 and set an “outperform” rating on the stock in a research report on Monday. Robert W. Baird restated a “sell” rating on shares of Amgen in a research report on Thursday, April 29th. The Goldman Sachs Group reiterated a “buy” rating and set a $290.00 price objective on shares of Amgen in a research note on Wednesday, April 28th. Credit Suisse Group dropped their target price on Amgen from $265.00 to $259.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Barclays decreased their price target on Amgen from $242.00 to $230.00 and set an “equal weight” rating for the company in a report on Thursday, March 11th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $255.62.

In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $238.40, for a total transaction of $238,400.00. Following the sale, the director now directly owns 16,805 shares in the company, valued at $4,006,312. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 11,110 shares of the company’s stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $236.51, for a total value of $2,627,626.10. The disclosure for this sale can be found here. Insiders sold a total of 14,360 shares of company stock valued at $3,407,034 in the last quarter. Insiders own 0.36% of the company’s stock.

NASDAQ AMGN traded down $0.29 during trading hours on Tuesday, hitting $245.09. The company had a trading volume of 103,440 shares, compared to its average volume of 2,714,429. The business has a 50 day moving average of $248.86 and a 200-day moving average of $236.11. The company has a market cap of $141.12 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The company has a debt-to-equity ratio of 3.12, a quick ratio of 1.88 and a current ratio of 2.28. Amgen Inc. has a 1-year low of $210.28 and a 1-year high of $276.69.

Amgen (NASDAQ:AMGN) last released its earnings results on Monday, April 26th. The medical research company reported $3.70 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $4.05 by ($0.35). Amgen had a return on equity of 95.55% and a net margin of 29.42%. The firm had revenue of $5.90 billion during the quarter, compared to analyst estimates of $6.30 billion. During the same quarter last year, the business posted $4.17 EPS. The firm’s revenue was down 4.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 16.15 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be issued a $1.76 dividend. The ex-dividend date is Friday, May 14th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 2.87%. Amgen’s dividend payout ratio is presently 47.50%.

About Amgen

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.

See Also: What Does a Sell-Side Analyst Rating Mean?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.